Abstract
The endocannabinoid system comprises amides, esters and ethers of long chain polyunsaturated fatty acids. Narachidonoylethanolamide (anandamide; ANA) and 2-arachidonoylglycerol (2-AG) are endogenous cannabinoids (endocannabinoids) ligands for the cannabinoid family of G-protein-coupled receptors named CB1 and CB2. Endocannabinoids are released upon demand from lipid precursors in a receptor-dependent manner and behave as retrograde signaling messengers, as well as modulators of postsynaptic transmission, interacting with other neurotransmitters systems. The two principal enzymes that are responsible for the metabolism of ANA and 2-AG are fatty acid amide hydrolase and monoacylglycerol lipase, respectively. Pharmacological experiments have shown that the administration of endocannabinoids induce cannabimimetic effects, including sleep promotion. This review will focus on some of the current evidence of the pharmacological potential of the endocannabinoid system on sleep modulation.
Keywords: Anandamide, cannabinoids, cannabidiol, rapid eye movement sleep, cannabinoid receptors, VDM-11
Central Nervous System Agents in Medicinal Chemistry
Title: The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation
Volume: 11 Issue: 3
Author(s): Eric Murillo-Rodriguez, Alwin Poot-Ake, Oscar Arias-Carrion, Elda Pacheco-Pantoja, Alfredo de la Fuente-Ortegon and Gloria Arankowsky-Sandoval
Affiliation:
Keywords: Anandamide, cannabinoids, cannabidiol, rapid eye movement sleep, cannabinoid receptors, VDM-11
Abstract: The endocannabinoid system comprises amides, esters and ethers of long chain polyunsaturated fatty acids. Narachidonoylethanolamide (anandamide; ANA) and 2-arachidonoylglycerol (2-AG) are endogenous cannabinoids (endocannabinoids) ligands for the cannabinoid family of G-protein-coupled receptors named CB1 and CB2. Endocannabinoids are released upon demand from lipid precursors in a receptor-dependent manner and behave as retrograde signaling messengers, as well as modulators of postsynaptic transmission, interacting with other neurotransmitters systems. The two principal enzymes that are responsible for the metabolism of ANA and 2-AG are fatty acid amide hydrolase and monoacylglycerol lipase, respectively. Pharmacological experiments have shown that the administration of endocannabinoids induce cannabimimetic effects, including sleep promotion. This review will focus on some of the current evidence of the pharmacological potential of the endocannabinoid system on sleep modulation.
Export Options
About this article
Cite this article as:
Murillo-Rodriguez Eric, Poot-Ake Alwin, Arias-Carrion Oscar, Pacheco-Pantoja Elda, de la Fuente-Ortegon Alfredo and Arankowsky-Sandoval Gloria, The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (3) . https://dx.doi.org/10.2174/187152411798047780
DOI https://dx.doi.org/10.2174/187152411798047780 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design N-Phenylamine Derivatives as Aggregation Inhibitors in Cell Models of Tauopathy
Current Alzheimer Research GSK-3 Inhibitors: Recent Developments and Therapeutic Potential
Current Signal Transduction Therapy Prion Disease: Chemotherapeutic Strategies
Infectious Disorders - Drug Targets Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Innovative Anthocyanin/Anthocyanidin Formulation Protects SK-N-SH Cells Against the Amyloid-β Peptide-Induced Toxicity: Relevance to Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Trigonelline: A Plant Alkaloid with Therapeutic Potential for Diabetes and Central Nervous System Disease
Current Medicinal Chemistry Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
Current Neuropharmacology Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Control of β-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-λ/ι and Nuclear Factor κ-B
Current Alzheimer Research New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Dopamine D1 Receptors, Regulation of Gene Expression in the Brain, and Neurodegeneration
CNS & Neurological Disorders - Drug Targets Circadian Timekeeping in Anticancer Therapeutics: An Emerging Vista of Chronopharmacology Research
Current Drug Metabolism Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Pleiotropic, Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids
Mini-Reviews in Medicinal Chemistry DNA Intercalators in Cancer Therapy: Organic and Inorganic Drugs and Their Spectroscopic Tools of Analysis
Mini-Reviews in Medicinal Chemistry Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology